-
Millennium Pharmaceuticals Inc. v. Hospira, Inc. DC CAFC
- 1:15-cv-00804
- D. Del.
- Filed: 09/10/2015
- Closed: 03/26/2018
- Latest Docket Entry: 03/26/2018
- Judge: Gregory M. Sleet
- PACER
1
Plaintiff
1
Defendant
1
Accused
Product
2
Patents-in-Suit
929
Days in
Litigation
-
Millennium Pharmaceuticals Inc. v. Hospira, Inc. DC CAFC
- 1:15-cv-00804
- D. Del.
- Filed: 09/10/2015
- Closed: 03/26/2018
- Latest Docket Entry: 03/26/2018
- Judge: Gregory M. Sleet
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 20 |
The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Invalid (103)
Entry 17 |
| 31 |
The method of claim 23, wherein the compound of formula (1) is D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Invalid (103)
Entry 17 |
| 49 |
A lyophilized cake comprising the compound of claim 20.
|
Invalid (103)
Entry 17 |
| 53 |
The method of claim 31 further comprising (c) reconstituting the lyophilized mixture with a pharmaceutically-acceptable carrier.
|
Invalid (103)
Entry 17 |
| All Claims |
NA
|
Valid
Entry 25 |
-
Infringement
Hospira Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 | All Asserted Claims |
Infringement
Entry 25
|